- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00000435
dnaJ Peptide for Relieving Rheumatoid Arthritis
A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Immune modulation is a promising new approach for the treatment of RA. Studies have shown that immune cells in the joints of people in the early stages of RA react strongly against dnaJ peptides from bacteria. These immune cells may also cross-react with human dnaJ peptides in the joints to cause inflammation. dnaJ may help RA by "re-educating" the immune system and dampening the abnormal inflammatory immune response in RA.
This study will last 7 months. Participants will be randomly assigned to receive either dnaJ or placebo by mouth. At screening, participants will have medical history, physical, and medication assessment. At screening, at 6 study visits every month after the start of treatment, and at 1 month follow-up, participants will have a joint exam, blood and urine collection, and will fill out a questionnaire about their condition.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85724-5093
- University of Arizona Health Sciences Center
-
-
California
-
Orange, California, Forente stater, 92868
- University of California, Irvine Medical Center
-
Palo Alto, California, Forente stater, 94305
- Stanford University
-
-
Colorado
-
Denver, Colorado, Forente stater, 80230
- Denver Arthritis Center
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21224
- Johns Hopkins University
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic
-
-
Pennsylvania
-
Sayre, Pennsylvania, Forente stater, 18840
- Guthrie Clinic
-
-
Washington
-
Seattle, Washington, Forente stater, 98104
- Virginia Mason Research Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Active rheumatoid arthritis as defined by the revised American College of Rheumatology (ACR) 1987 criteria. Evidence of active disease will be based on at least six swollen or nine tender joints.
- Diagnosis of rheumatoid arthritis of less than 5 years
- Reactivity to dnaJ
- Agree to use acceptable methods of contraception
- Able to understand and sign informed consent
Exclusion Criteria:
- Patients taking more 7.5 mg of prednisone or disease modifying agents other than hydrochloroquine or sulfasalazine (i.e., gold, penicillamine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, or anti-TNF agents)
- Serum creatinine greater than 1.5 mg/dl
- SGOT less than SGPT
- Alkaline phosphatase greater than 2 times age/sex adjusted normal values
- Hematocrit of less than 30
- Platelets less than 130,000
- History of lymphoma
- Any active malignancy or cancer requiring treatment in the last 5 years, except for nonmelanoma skin cancers and carcinoma of the cervix in situ
- Medical or psychiatric condition or active serious infection
- Pregnant or breastfeeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: A
Subjects randomized to arm A received 25mg/day po of placebo
|
placebo was taken in pill form at 25mg/day for 6 months
|
Aktiv komparator: B
Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
|
dnaJP1 was taken in pill form at 25mg/day for 6 months
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Area under the curve or 'AUC' obtained by adding 0 for no response and 1 for an ACR 20 response for visits on Day 112, 140, and 168
Tidsramme: time points 112, 140 and 168 of the 6-month trial
|
time points 112, 140 and 168 of the 6-month trial
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Day 112 ACR 20 score
Tidsramme: Visit day 112 of the 6-month trial
|
Visit day 112 of the 6-month trial
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Salvatore Albani, MD, University of California, San Diego
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, Amox D, Roord S, de Kleer I, Bonnin D, Lanza P, Berry C, Massa M, Billetta R, Albani S. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4228-33. doi: 10.1073/pnas.0400061101. Epub 2004 Mar 15.
- Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Kavanaugh A, Molitor JA, Schiff MH, Posever JO, Bathon JM, Kivitz AJ, Samodal R, Belardi F, Dennehey C, van den Broek T, van Wijk F, Zhang X, Zieseniss P, Le T, Prakken BA, Cutter GC, Albani S. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009 Nov;60(11):3207-16. doi: 10.1002/art.24916.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- N01 AR92241
- NIAMS-042
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på None-placebo
-
Taiho Pharmaceutical Co., Ltd.RekrutteringDuchenne muskeldystrofiJapan
-
Cliniques universitaires Saint-Luc- Université...Fullført
-
AstraZenecaFullførtBrystkreft | Onkologi | EpidemiologiAlgerie
-
Monash University MalaysiaFullførtPsykisk helseproblemMalaysia
-
University of UtahFullførtHøyrisikograviditetForente stater
-
Indiana UniversityMayo Clinic; National Institute on Aging (NIA); University of Minnesota; Regenstrief... og andre samarbeidspartnereHar ikke rekruttert ennåDemens | Alzheimers sykdom | SøvnforstyrrelserForente stater
-
Mayo ClinicFullførtHypotensjonForente stater
-
Masimo CorporationFullført
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutteringDiaré | Sløsing | Underernæring, barnKenya
-
Andres Duque DuqueZimmer BiometUkjent